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Background: Phosphodiesterase (PDE) inhibitors, such as cilostazol and pentoxifylline, are associated with vasodilatory effects mediated by 
changes in cAMP levels in smooth muscle cells. Cilostazol is also associated with enhanced platelet inhibitory effects by increasing cAMP levels in 
patients on dual antiplatelet therapy (DAPT), a phenomenon which is marked in diabetes mellitus (DM) patients. Although pentoxifylline may reduce 
platelet reactivity in vitro, it’s ex vivo effects in DM patients treated with DAPT are unknown.
Methods: This was a prospective, randomized, double-blind study conducted in 40 DM patients. All patients had stable coronary artery disease 
and were on DAPT with aspirin and clopidogrel. Patients were randomly assigned to either pentoxifylline 400mg or placebo three times daily for 
14 days. Pharmacodynamic (PD) effects were assessed by vasodilator-stimulated phosphoprotein phosphorylation (VASP) assay, VerifyNow P2Y12 
system, and light transmittance aggregometry (LTA) at baseline and 14 days.
Results: Patients randomized to pentoxifylline (n=20) or placebo (n=20) were matched for clinical characteristics. At baseline, there were no 
differences in PD measures between patients randomized to pentoxifylline or placebo. At 14 days, there were no significant differences in PD 
measures between treatment groups (Table).
Pharmacodynamic Effects of Pentoxifylline versus Placebo
Pentoxifylline Placebo P value
PRI (%) (mean ± SD) 62.0±16.8 64.1±17.7 0.55
20 μM ADP (%) (mean ± SD) 55.4±10.1 50.9±11.9 0.22
5 μM ADP (%) (mean ± SD) 45.7±11.9 38.4±13.4 0.07
VerifyNow PRU (mean ± SD) 269±97 245±72 0.37
Conclusion: Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients on DAPT.
